arrow
E

Erminia Massarelli

City of Hope National Medical Center
H指数:43
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 trial

奥希替尼联合巩固性放疗治疗晚期EGFR突变非小细胞肺癌:一项多中心、单臂、II期临床试验

2025-08-260
PREAI
Response to Letter to the Editor From Zhang et al: Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer

张等人的来信回复:卡博替尼联合伊匹木单抗/纳武利尤单抗治疗既往接受过治疗的分化型甲状腺癌患者

2025-04-040
OA
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

卡博替尼联合阿特珠单抗或单用卡博替尼治疗先前接受免疫检查点抑制剂治疗的晚期NSCLC患者: 1b COSMIC-021期研究的结果

2024-10-011
OA
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer

卡博替尼联合Ipilimumab/Nivolumab治疗先前治疗的晚期分化型甲状腺癌患者

2024-08-121
OA
Non-Small Cell Lung Cancer, Version 4.2024

非小细胞肺癌4.2024版

2024-05-0150
PRE
NCCN Continuing Education
2024-03-016
OA
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib联合西妥昔单抗治疗KRAS G12C-positive结直肠癌: 1b期临床试验

2023-12-0531
OAAI
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
2023-10-1319
OAAI
Mesothelioma: Peritoneal, Version 2.2023
2023-09-019
OA
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

单药Divarasib (GDC-6036) 在具有KRAS G12C突变的实体瘤中

2023-08-2495
OA